Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 13/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | ECE1 | P42892 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8413844 | 1.00 | CASP1 (0.51) | CASP1ALDH1A1MAPK1L3MBTL1GAA | |
| SCHEMBL21555767 | 0.93 | ALDH1A1 (0.51) | CASP1ALDH1A1MAPK1L3MBTL1MAPT | |
| SCHEMBL22522926 | 0.89 | ABCB1 (0.48) | ALDH1A1MAPK1L3MBTL1MAPTSLC15A1 | |
| SCHEMBL19749933 | 0.89 | ALDH1A1 (0.48) | ALDH1A1MAPK1L3MBTL1MAPTSLC15A1 | |
| SCHEMBL19512002 | 0.88 | ALDH1A1 (0.53) | CASP1ALDH1A1MAPK1L3MBTL1HTT | |
| SCHEMBL22424808 | 0.87 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1SLC15A1MME | |
| SCHEMBL19749931 | 0.87 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1MAPTSLC15A1 | |
| SCHEMBL28409360 | 0.86 | FOLH1 (0.55) | ALDH1A1MAPK1L3MBTL1GAAMME | |
| SCHEMBL28409358 | 0.86 | FOLH1 (0.55) | ALDH1A1MAPK1L3MBTL1GAAMME | |
| SCHEMBL23011535 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1MAPTSLC15A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3239142-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-9975903-B2 | Condensed heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20170349605-A1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-07 | — | — | US | disclosed |
| EP-3239142-A1 | CONDENSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-11-01 | — | — | EP | disclosed |
| EP-0934260-A1 | N ALPHA-2-(4-NITROPHENYLSULFONYL)ETHOXYCARBONYL-AMINO ACIDS | Hyundai Pharm. Ind. Co., Ltd. (KR) | 1999-08-11 | — | — | EP | disclosed |
| CN-1187490-A | 5-membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | HOECHST AG (DE) | 1998-07-15 | — | — | CN | disclosed |
| WO-1998017638-A1 | Nα-2-(4-NITROPHENYLSULFONYL)ETHOXYCARBONYL-AMINO ACIDS | HYUNDAI PHARM. IND. CO., LTD. (KR) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349605-A1 | CONDENSED HETEROCYCLIC COMPOUND | VIP, TMPRSS15, MMP2 | CASP1 263/4885ALDH1A1 996/4885MAPK1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.